The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

June 01, 2021

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

June 01, 2021

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

May 28, 2021

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

May 27, 2021

Kanwal Raghav, MBBS, MD, discusses current sequencing approaches in metastatic colorectal cancer.

May 26, 2021

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

May 26, 2021

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.

May 19, 2021

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

May 14, 2021

UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.

May 13, 2021

Helen J. Ross, MD, discusses the utility of first- and second-generation EGFR inhibitors in EGFR-mutant non–small cell lung cancer.

May 11, 2021

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer.

May 10, 2021

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

May 05, 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

May 04, 2021

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

May 03, 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

April 28, 2021

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

April 20, 2021

Richard Gorlick, MD, discusses the potential of antibody-drug conjugates in patients with osteosarcoma.

April 15, 2021

Richard Gorlick, MD, highlights methods for identifying immunotherapeutic targets in osteosarcomas.

April 15, 2021

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

April 12, 2021

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

April 07, 2021

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.